On September 5, 2019, Medium elemental featured insights from AFAR expert Nir Barzilai, MD, on the potential of the AFAR-managed TAME Trials to transform healthspan through drugs like metformin to treat aging.
“Based on what scientists have already observed with diabetic and prediabetic patients taking metformin,” the article states, “Barzilai is confident the drug has a beneficial effect on the biological mechanisms underlying aging.”
On the TAME trials, the article says, “TAME mainly seeks to answer the question of whether metformin will help lengthen life and stave off disease.”
Dr. Barzilai is AFAR’s Deputy Scientific Director, a 1994 AFAR Research Grant recipient, and a 1997 Paul B. Beeson Emerging Leaders Career Development Award in Aging scholar, as well as the Director at the Institute for Aging Research and a distinguished Professor at the Albert Einstein College of Medicine.
Learn more about the TAME Trials, which AFAR will manage, here.
Read the article, “The Safe, Boring, and Extremely Cheap Drug That Could Cure Aging,” here.
